NASDAQ
Keros Therapeutics, Inc. (KROS)
♥ 537 Thanks from members
Keros Therapeutics (KROS) faces a revenue visibility gap with zero product sales and Q2 2026 losses widening to $1.45 per share, though its pipeline advances—highlighted by a $20M Takeda milestone and a Phase 2 DMD trial for rinvatercept—support a $257.6M cash runway stretching into early 2028.